CONMEDNYSE: CNMD

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

CONMED (CNMD) exceeded expectations for adjusted first-quarter earnings and revenues due to strong performance in both U.S. and International markets, as well as improvements in the supply chain.

End Call: CONMED Corporation (NYSE: CNMD) Q1 2024 Earnings Conference Call on April 24, 2024 at 4:30 PM ET. Presenters include Curt Hartman, Todd Garner, and various conference call participants. Thank you for joining CONMED's Q1 FY 2024 Earnings Conference Call.

The performance of Conmed (CNMD) in the quarter ending March 2024 can be understood from the headline numbers, but it could be beneficial to analyze its key metrics in comparison to Wall Street estimates and the previous year's results.

Conmed (CNMD) reported earnings of $0.79 per share for the quarter, surpassing the Zacks Consensus Estimate of $0.74 per share. This is an improvement from earnings of $0.66 per share in the same quarter last year.

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Despite significant challenges, the U.S. economy has showcased remarkable resilience. Fears of an imminent recession have been allayed by two consecutive quarters of robust GDP growth exceeding 3%.

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.